Ad hoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership




  • Evotec SE announces today that the Company has extended and expanded its strategic partnership with Bristol Myers Squibb (NYSE:BMY) in neurodegeneration, originally signed in 2016. Aim of the 8-year extension of the strategic alliance is to further broaden the programme pipeline in neurodegenerative diseases.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-bristol-myers-squibb-expand-strategic-neurodegeneration-partnership-6271

    Du magst vielleicht auch